2 of the best ASX 200 blue-chip shares to buy in May

These blue chips are best buys according to a couple of leading brokers.

| More on:
A group of businesspeople clapping.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are plenty of blue-chip shares on the ASX 200 index. But which ones could be buys in May?

Let's take a look at two shares that are rated as best buys by a couple of leading brokers right now. They are as follows:

Coles Group Ltd (ASX: COL)

Analysts at Morgans think that this supermarket giant would be a great ASX 200 blue-chip share to buy this month. So much so, the broker has added it to its best ideas list in May.

It believes that recent share price weakness has created a buying opportunity for investors. The broker said:

In our view, the ongoing scrutiny on the supermarkets has affected short term sentiment in the sector, which we believe creates a good buying opportunity in COL. While Liquor sales remain soft, we expect the core Supermarkets division (~92% of earnings) to continue to be supported by further improvement in product availability, reduction in total loss, greater in-home consumption due to cost-of-living pressures, and population growth.

Morgans currently has an add rating and $18.95 price target on the company's shares. This implies a potential upside of 15% for investors over the next 12 months. The broker also expects a ~4% fully franked dividend yield from its shares.

ResMed Inc. (ASX: RMD)

The team at Bell Potter has named this sleep disorder treatment company as an ASX 200 blue-chip share to buy. Its analysts have ResMed on their Australian Equities Panel. These are the broker's favoured Australian equities that offer attractive risk-adjusted returns over the long term.

Bell Potter likes the company due to its significant opportunity as a leader in obstructive sleep apnoea (OSA) and other sleep disorders. It said:

The market for OSA and chronic obstructive pulmonary disease (COPD) remains under penetrated, and we expect industry volume growth to continue in the 6-8% range for the foreseeable future. In this regard, the competitive dynamics are very much in favour of RMD due to the Philips recall and improving semiconductor availability. Looking ahead, ResMed continues to expect device sales to be sequentially higher throughout CY2023. Furthermore, ResMed is well-positioned to build on its dominant share even after Philips returns to the global market, with the launch of its latest continuous positive airway pressure (CPAP) device, the Air Sense 11.

The broker has a buy rating and a $36.00 price target on its shares. This suggests a potential upside of 9% is possible over the next 12 months.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended Coles Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Blue Chip Shares

2 of the best ASX 200 blue chip shares to buy with $2,000

One leading broker has very good things to say about these buy-rated shares.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Blue Chip Shares

Is it too late to buy this $33 billion ASX 200 stock?

Do analysts think this popular stock can deliver good returns for investors? Let's find out.

Read more »

Excited couple celebrating success while looking at smartphone.
Blue Chip Shares

2 high-quality ASX 200 blue chip shares to buy with $2,000 in February

These shares are highly rated by analysts at Bell Potter. But why?

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

The one Australian stock to buy and hold forever in an ASX share portfolio

Buy and hold investing could be your ticket to wealth. Let's see why.

Read more »

Six smiling health workers pose for a selfie.
Blue Chip Shares

Should you buy CSL and ResMed shares in January?

Let's see what one leading broker is saying about these blue chips.

Read more »

Two people tired and resting after sports race.
Blue Chip Shares

Value + yield: 2 battered blue-chip ASX dividend shares that demand attention

I think these stocks could be very compelling for income.

Read more »

Excited couple celebrating success while looking at smartphone.
Blue Chip Shares

3 of the best ASX 200 blue chip shares to buy in January

Let's see why brokers are tipping these blue chips as buys this month.

Read more »

A man is shocked about the explosion happening out of his brain.
Blue Chip Shares

3 no-brainer ASX 200 blue chip stocks to buy this month

Analysts think these stocks are high quality options for blue chip investors.

Read more »